Prednisolone is the Preferred Oral Glucocorticoid for Respiratory Diseases
For respiratory diseases, prednisolone should be used as the preferred oral glucocorticoid over deflazacort. Prednisolone has extensive evidence supporting its use across multiple respiratory conditions, is specifically recommended in major clinical guidelines, and has FDA approval for a broad range of respiratory indications 1.
Evidence-Based Rationale
Guideline and Regulatory Support
The 2017 GOLD guidelines for COPD exacerbations explicitly recommend 40 mg prednisone (or prednisolone equivalent) daily for 5 days as the standard systemic glucocorticoid regimen 2. This recommendation is based on Level A evidence showing that systemic glucocorticoids improve lung function (FEV1), oxygenation, shorten recovery time, and reduce hospitalization duration 2. Notably, oral prednisolone is equally effective to intravenous administration 2.
The FDA-approved indications for prednisolone specifically include 1:
- Asthma (both allergic and non-allergic)
- Acute exacerbations of COPD
- Symptomatic sarcoidosis
- Idiopathic eosinophilic pneumonias
- Hypersensitivity pneumonitis
- Idiopathic pulmonary fibrosis
- Allergic bronchopulmonary aspergillosis
- Idiopathic bronchiolitis obliterans with organizing pneumonia
Deflazacort's Limited Respiratory Evidence
In stark contrast, deflazacort's FDA approval is exclusively for Duchenne muscular dystrophy (DMD) 3. The clinical trials supporting deflazacort evaluated muscle strength in pediatric patients with DMD—not respiratory outcomes 3. While deflazacort is technically a glucocorticoid, it lacks the robust evidence base and regulatory approval for respiratory diseases that prednisolone possesses.
Comparative Clinical Data
The limited head-to-head studies comparing these agents in respiratory disease show:
A 2004 pediatric study found deflazacort (1.5 mg/kg) and prednisolone (1 mg/kg) had similar efficacy in moderate acute asthma, with comparable improvements in FEV1, PEFR, and symptom scores 4. However, this equivalence does not establish superiority for deflazacort.
A 1995 study in severe asthma crises found deflazacort "as effective as prednisone" 5—again, equivalence, not superiority.
A 2026 narrative review noted that deflazacort "shows comparable efficacy but requires further validation" in pediatric respiratory disease 6.
Critical Clinical Considerations
Common pitfall to avoid: Do not assume deflazacort is "safer" or has fewer side effects in respiratory disease. While older marketing materials made such claims, these were withdrawn by regulatory authorities due to insufficient evidence 7. The 1999 Drug and Therapeutics Bulletin concluded that deflazacort offered no clear advantages over prednisolone 7.
Dosing precision: Prednisolone has well-established, evidence-based dosing regimens for specific respiratory conditions (e.g., 40 mg daily for COPD exacerbations, 0.5-0.75 mg/kg for organizing pneumonia 2, 8). Deflazacort lacks such validated protocols for respiratory diseases.
Cost and availability: Prednisolone is widely available, inexpensive, and familiar to clinicians. Deflazacort is more expensive and primarily stocked for DMD patients.
Clinical Algorithm
Use prednisolone for:
- COPD exacerbations: 40 mg daily × 5 days 2
- Asthma exacerbations: 1 mg/kg daily (max 40-60 mg) × 5-7 days
- Post-COVID organizing pneumonia: 0.5 mg/kg daily with structured taper 8
- Other inflammatory respiratory conditions per FDA indications 1
Consider deflazacort only if:
- Patient has documented intolerance to prednisolone (rare)
- Patient is already on deflazacort for DMD and develops a respiratory exacerbation requiring glucocorticoid therapy
Never use deflazacort as first-line for respiratory diseases given the lack of disease-specific evidence, absence of FDA approval for these indications, and well-established efficacy of prednisolone.